Proyectos destacados

Non-invasive molecular brain imaging in Early-onset Psychosis: unraveling the Neurobiological Substrate of Psychotic Symptoms, Cognitive Dysfunction and Response to Antipsychotic Treatment

Investigador/a principal: Gisela Sugranyes Ernest.
Financiador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Instituto de Salud Carlos III .

Código: PI24/00279.

Duración: 01/01/2025 - 31/12/2027
Avances clave para la investigación de impacto en FRCB-IDIBAPS (KAIROS)

Investigador/a principal: Gisela Sugranyes Ernest.
Financiador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Instituto de Salud Carlos III .

Código: FORT23/00002_SUGR_G6.

Duración: 01/01/2024 - 31/12/2027
Imaging glutamatergic transmission and its brain structural and functional correlates during the neurodevelopmental pathway leading to schizophrenia: from rodents to humans

Investigador/a principal: Gisela Sugranyes Ernest.
Financiador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Fundació La Marató de TV3 .

Código: 202232-30.

Duración: 19/05/2023 - 18/05/2026
Running in the FAMILY. Undrestanding and predicting the intergenerational transmission of mental illness

Investigador/a principal: Gisela Sugranyes Ernest.
Financiador: European Commission .

Código: CE_HE_CH_21_1s21_RIA.

Duración: 01/10/2022 - 30/09/2027
Markers of glutamatergic dysfunction in adolescents at increased risk for psychosis: relationship with brain structure, symptoms and oxidative stress

Investigador/a principal: Gisela Sugranyes Ernest.
Financiador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Instituto de Salud Carlos III ; Fundación Alicia Koplowitz .

Código: PI02100330.

Duración: 01/01/2022 - 01/01/2025
Construction of a multimodal model with diagnostic and prognostic potential in youth at high risk for psychosis: integration of genetic, environmental and neuroimaging factors

Investigador/a principal: Gisela Sugranyes Ernest.
Financiador: Fundació Clínic Recerca Biomèdica (Sede o evento); Ajut a la Recerca Pons Bartran. Fundació Clínic Recerca Biomèdica (Sede o evento); Instituto de Salud Carlos III .

Duración: 01/01/2019 - 30/06/2023

Resumen:
Ayuda a la Investigación Pons Bartran
Early perceptual processing in adolescents with recent onset schizophrenia and patients with NMDA receptor encefalitis: assessment of the glutamatergic hypothesis of schizophrenia

Investigador/a principal: Gisela Sugranyes Ernest.
Financiador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Generalitat de Catalunya .

Código: SLT006/17/00362.

Duración: 17/02/2018 - 31/12/2021
NARSAD Young Investigator Award. From the synapse to brain structure and function: a comparative study between youth with early stage psychosis and patients with NMDA Receptor Encephalitis

Investigador/a principal: Gisela Sugranyes Ernest.
Financiador: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (Sede o evento); Brain Behaviour Foundation .

Código: NARSAD17_YIG_02B.

Duración: 15/02/2018 - 14/07/2021
Effect of a 48-week course of N-acetylcysteine (NAC) as add-on treatment on gray matter loss and oxidative metabolism, symptoms and functioning in early-onset first-episode psychosis: a randomized, double-blind, placebo-controlled clinical trial. Proyecto

Financiador: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (Sede o evento); CONSORCIO CIBER PARA EL AREA TEMATICA DE SALUD MENTAL (CIBERSAM) .

Duración: 01/01/2014 - 01/01/2018
Estudio longitudinal de primeros episodios psicóticos en la infancia y adolescencia. Seguimiento a 10 años. Proyecto de Investigación ISCII PI13/00614

Investigador/a principal: Gisela Sugranyes Ernest.
Financiador: Instituto de Salud Carlos III .

Código: PI13/00614.

Duración: 01/01/2014 - 30/06/2018

La investigación de este grupo se puede llevar a cabo gracias a los financiadores.

Proyectos destacados

Non-invasive molecular brain imaging in Early-onset Psychosis: unraveling the Neurobiological Substrate of Psychotic Symptoms, Cognitive Dysfunction and Response to Antipsychotic Treatment

Avances clave para la investigación de impacto en FRCB-IDIBAPS (KAIROS)

Imaging glutamatergic transmission and its brain structural and functional correlates during the neurodevelopmental pathway leading to schizophrenia: from rodents to humans

Running in the FAMILY. Undrestanding and predicting the intergenerational transmission of mental illness

Markers of glutamatergic dysfunction in adolescents at increased risk for psychosis: relationship with brain structure, symptoms and oxidative stress

Construction of a multimodal model with diagnostic and prognostic potential in youth at high risk for psychosis: integration of genetic, environmental and neuroimaging factors

Early perceptual processing in adolescents with recent onset schizophrenia and patients with NMDA receptor encefalitis: assessment of the glutamatergic hypothesis of schizophrenia

NARSAD Young Investigator Award. From the synapse to brain structure and function: a comparative study between youth with early stage psychosis and patients with NMDA Receptor Encephalitis

Effect of a 48-week course of N-acetylcysteine (NAC) as add-on treatment on gray matter loss and oxidative metabolism, symptoms and functioning in early-onset first-episode psychosis: a randomized, double-blind, placebo-controlled clinical trial. Proyecto

Estudio longitudinal de primeros episodios psicóticos en la infancia y adolescencia. Seguimiento a 10 años. Proyecto de Investigación ISCII PI13/00614

Principales financiadores